Substance-abuse disorders (SADs) are not at all uncommon among patients with heart failure (HF), according to a study. Several SADs independently correlate with HF-related emergency department (ED) visits and hospitalizations.
A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.
The oral Janus kinase inhibitor tofacitinib appears to have no benefit for the extraintestinal manifestations* (EIMs) of moderate-to-severe ulcerative colitis (UC), according to data from the OCTAVE** clinical programme presented at AIBD 2019.
Treatment with intravenous immunoglobulin (IVIG) offers significant pain relief in patients with painful diabetic polyneuropathy (DPN) resistant to standard therapies, without deleterious side effects, according to the results of a trial.
A single infusion of infliximab effectively resolves fever in paediatric patients with acute Kawasaki disease (KD) refractory to conventional therapies, a Japan study performed in the real-world clinical setting has shown. In addition, it is well tolerated, with no new safety concerns seen.
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.